Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-α synthesis

This publication has 12 references indexed in Scilit:

• The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-α and nitric oxide
  International Journal of Immunopharmacology, 1995
• Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids
  European Journal of Immunology, 1995
• Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor
  International Journal of Immunopharmacology, 1994
• Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
  The Lancet, 1994
• TUMOR NECROSIS FACTOR: A Pleiotropic Cytokine and Therapuetic Target
  Annual Review of Medicine, 1994
• Prostacyclin analogs suppress the synthesis of tumor necrosis factor-α in LPS-stimulated human peripheral blood mononuclear cells
  Immunopharmacology, 1993
• The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells
  International Journal of Immunopharmacology, 1993
• Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli.
  Journal of Clinical Investigation, 1991
• Cyclic nucleotide phosphodiesterases: Pharmacology, biochemistry and function
  Pharmacology & Therapeutics, 1991
• Pharmacokinetics and pharmacodynamics of cicaprost in healthy volunteers after oral administration of 5 to 20 ?G
  European Journal of Clinical Pharmacology, 1990